A once-a-week shot from Australian scientists could spare people with Parkinson's the grind of taking pills several times a day.
The tiny, biodegradable gel sits under the skin and releases steady doses of two key medicines all week long, aiming for steadier symptom control, fewer side effects, and a much simpler routine. Early lab tests look safe and effective, and the team hopes to move into human trials soon.
Weekly Injectable Breakthrough for Parkinson's
A once-a-week injection could greatly ease life for the more than eight million people who live with Parkinson's disease by replacing the daily routine of swallowing multiple pills.
Researchers at the University of South Australia (UniSA) have designed a long-acting shot that supplies a steady, seven-day dose of levodopa and carbidopa, the two main medicines used to control Parkinson's symptoms.
Details of their work appear in the journal Drug Delivery and Translational Research.
Biodegradable Delivery System Cuts Pill Burden
The formulation, made from biodegradable materials, is injected just under the skin or into muscle. It then releases the medication gradually for an entire week.
Parkinson's disease is the world's second most common neurological condition, affecting more than 8.5 million people. Although no cure exists, tremors, stiffness, and slowed movement can be managed with oral drugs that often have to be taken several times a day.
This frequent dosing can be hard on patients, especially older adults or anyone who has trouble swallowing tablets. Irregular timing of doses causes uneven drug levels, extra side effects, and less dependable relief.
Researchers Highlight Life-Changing Potential
Lead researcher Professor Sanjay Garg, from UniSA's Centre for Pharmaceutical Innovation, says the newly developed injectable could significantly improve treatment outcomes and patient adherence.
"Our goal was to create a formulation that simplifies treatment, improves patient compliance, and maintains consistent therapeutic levels of medication. This weekly injection could be a game-changer for Parkinson's care," Prof Garg says.
"Levodopa is the gold-standard therapy for Parkinson's, but its short life span means it must be taken several times a day."
Steady Week-Long Release via Smart Polymer Gel
UniSA PhD student Deepa Nakmode says the in-situ implant is designed to release both levodopa and carbidopa steadily over one week, maintaining consistent plasma levels and reducing the risks associated with fluctuating drug concentrations.
"After years of focused research, it's incredibly rewarding to see our innovation in long-acting injectables for Parkinson's disease reach this stage. Our invention has now been filed for an Australian patent," Nakmode says.
The injectable gel combines an FDA-approved biodegradable polymer, PLGA, with Eudragit L-100, a pH-sensitive polymer, to achieve a controlled and sustained drug release.
Lab Results Show High Release and Safety
Extensive lab tests confirmed the system's effectiveness and safety:
- More than 90% of the levodopa dose and more than 81% of the carbidopa dose were released over seven days.
- The implant degraded by over 80% within a week and showed no significant toxicity in cell viability tests.
- The formulation can be easily administered through a fine 22-gauge needle, minimizing discomfort and eliminating the need for surgical implant.
Broader Impact and Path Toward Clinical Trials
"The implications of this research are profound," Prof Garg says. "By reducing the frequency of dosing from multiple times a day to a weekly injection is a major step forward in Parkinson's therapy. We're not just improving how the drug is delivered; we're improving patients' lives."
Prof Garg says the technology could also be adapted for other chronic conditions such as cancer, diabetes, neurodegenerative disorders, pain management, and chronic infections that require long-term drug delivery.
The system can be tuned to release drugs over a period ranging from a few days to several weeks depending on therapeutic needs.
UniSA scientists hope to start clinical trials in the near future and are exploring commercialization opportunities.
Reference: "Development of an in-situ forming implant system for levodopa and carbidopa for the treatment of parkinson's disease" by Deepa D. Nakmode, Sadikalmahdi Abdella, Yunmei Song and Sanjay Garg, 7 June 2025, Drug Delivery and Translational Research.
DOI: 10.1007/s13346-025-01892-y
News
Scientists Develop a Clever New Way To Kill Cancer Cells From the Inside
Scientists have developed an experimental strategy that exploits a chemical byproduct of cancer cells to produce anticancer drugs directly inside them. Scientists in Japan have developed an experimental method that uses a chemical produced [...]
Our books are available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
After only a short training, people in a coma managed to send targeted signals
Researchers have succeeded in communicating with brain-injured patients who are unconscious. They see enormous potential in this for future treatments. Patients who lie motionless in bed after a severe brain injury and do not [...]
MIT Scientists Reprogram Immune Cells Inside the Body To Destroy Cancer
Natural killer cells reprogrammed inside mice eliminated lymphoma tumors and helped damaged livers heal, though whether this approach could help people with cancer or autoimmune disease remains unknown. To make a cancer treatment from [...]
Melanoma mRNA Vaccine Shows Promise in Preventing Disease Recurrence
Key takeaways: Phase 3 trial finds personalized intismeran plus pembrolizumab may better prevent high-risk melanoma recurrence after surgery The trial enrolled 1,137 patients and builds on phase 2 results showing about half the recurrence [...]
Scientists Discover a Powerful New Weapon Against a Dangerous Gut Infection
The promise of an experimental treatment for C. difficile gut infections lies partly in the bacteria it leaves alive, according to early laboratory and mouse research. Broad-spectrum antibiotics can disrupt the gut’s microbial community, [...]
Your Bones May Hold a Hidden Clue to Blood Cancer Survival
For people with blood cancers called myelodysplastic syndromes, osteoporosis may hold an overlooked clue to survival, a three-year observational study suggests. In blood cancers that develop in the bone marrow, an important clue to [...]
Researchers Discover What Reading for Pleasure May Be Doing to Your Brain
Reading for pleasure may offer surprising benefits for the brain, with research linking the habit to better mental health, stronger cognitive abilities, and a lower risk of dementia. Reading for pleasure may do far [...]
Scientists Discover a Hidden Trigger That Keeps Inflammation Alive
Inflammation persists after proteins detach from immune receptors, revealing a potential target for autoimmune treatments. Since a Nobel Prize-winning discovery in the 1990s identified molecules called Toll-like Receptors as the guardians of the human [...]
A Virus Gives Itself Away the Moment It Attacks
Researchers have found the trigger behind a powerful bacterial defense against viruses. Viruses that prey on bacteria could become an increasingly important tool for treating bacterial infections, particularly as antibiotic resistance makes some infections [...]
Scientists Discover Aspirin May Slash Dementia Risk by 70% – but Only for Certain People
Aspirin was linked to a sharply lower dementia risk in some older adults, and their genes may hold the clue. A Monash University analysis found that older adults with a particular genetic profile had [...]
Inflammation May Awaken Dormant Cancer Cells Years After Treatment
The body’s response to inflammation may disturb cancer cells that have been lying silent for years, giving them an opportunity to grow again. Researchers at the Francis Crick Institute have found that gut inflammation [...]
Where do nanoparticles go once they enter the body?
New international best practice guidance, co-written at ANSTO, sets out how to measure where nanoparticles like titanium dioxide end up in the body and how long they remain. The guidance has been shared by [...]
Long-Acting HIV Shots Could Solve a Major Treatment Challenge for Young People
A major African trial suggests that changing how HIV treatment is delivered could significantly improve viral suppression in adolescents. Young people with HIV were more likely to keep the virus suppressed when they received [...]
WHO Factsheets – The top 10 causes of death
In 2023, the 10 leading causes of death accounted for 33 million deaths, or 54% of the total 61 million deaths worldwide. The top global causes of death, in order of total number of lives lost, [...]
Aging Cells May Be Hiding From the Immune System – Scientists Think They Know How
Your immune system is supposed to clear out damaged cells. Researchers may have found how some of them hide and linger as the body ages. Researchers led by Cedars-Sinai Health Sciences University have identified [...]
